Celldex Therapeutics (CLDX)
Develops KIT and bispecific antibodies for mast-cell-driven inflammatory diseases.
$37.93
vs last close+0.04 (+0.11%)
Something off on this page? Send us feedback.
Next report
Nov 9, 26
in 48 days
EPS estimate
−$1.02
Revenue estimate
$722.6K
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported−$0.71−$0.81−$0.85−$1.01−$1.22−$1.18−$0.94Pending
Estimate−$0.73−$0.75−$0.86−$0.88−$1.00−$1.15−$1.06−$1.02
Surprise+2.7%−8.0%+1.2%−14.8%−22.0%−2.9%+11.3%—
RevenueReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported$1.2M$695.0K$730.0K—$100.0K$15.0K$22.0KPending
Estimate$1.0M$997.6K$1.0M$985.8K$1.3M$795.4K$734.9K$722.6K
Surprise+14.7%−30.3%−29.1%—−92.4%−98.1%−97.0%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2027 | −$1.19 | — | — |
| Sep 2027 | −$1.05 | — | — |
| Jun 2027 | −$0.97 | — | — |
| Mar 2027 | −$1.03 | — | — |
| Dec 2026 | −$1.02 | — | — |
| Nov 2026 | −$1.02 | — | — |
| Aug 2026 | −$1.06 | −$0.94 | +11.3% |
| May 2026 | −$1.15 | −$1.18 | −2.9% |
| Feb 2026 | −$1.00 | −$1.22 | −22.0% |
| Nov 2025 | −$0.88 | −$1.01 | −14.8% |
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Feb 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Feb 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Mar 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Mar 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Mar 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Feb 2016 | |||
| Nov 2015 | |||
| Aug 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2027 | −$1.19 | — | — | $333.3K | — | — | — |
| Sep 2027 | −$1.05 | — | — | $333.3K | — | — | — |
| Jun 2027 | −$0.97 | — | — | $250.0K | — | — | — |
| Mar 2027 | −$1.03 | — | — | $440.0K | — | — | — |
| Dec 2026 | −$1.02 | — | — | $1.2M | — | — | — |
| Nov 9, 2026 | −$1.02 | — | — | $722.6K | — | — | — |
| Aug 6, 2026 | −$1.06 | −$0.94 | +11.3% | $734.9K | $22.0K | −97.0% | +0.4% |
| May 7, 2026 | −$1.15 | −$1.18 | −2.9% | $795.4K | $15.0K | −98.1% | −3.1% |
| Feb 25, 2026 | −$1.00 | −$1.22 | −22.0% | $1.3M | $100.0K | −92.4% | +24.1% |
| Nov 10, 2025 | −$0.88 | −$1.01 | −14.8% | $985.8K | — | — | −1.0% |
| Aug 7, 2025 | |||||||
| May 8, 2025 | |||||||
| Feb 27, 2025 | |||||||
| Nov 6, 2024 | |||||||
| Aug 8, 2024 | |||||||
| May 6, 2024 | |||||||
| Feb 26, 2024 | |||||||
| Nov 2, 2023 | |||||||
| Aug 8, 2023 | |||||||
| May 4, 2023 | |||||||
| Feb 28, 2023 | |||||||
| Nov 9, 2022 | |||||||
| Aug 8, 2022 | |||||||
| May 5, 2022 | |||||||
| Feb 28, 2022 | |||||||
| Nov 9, 2021 | |||||||
| Aug 5, 2021 | |||||||
| May 6, 2021 | |||||||
| Mar 29, 2021 | |||||||
| Nov 5, 2020 | |||||||
| Aug 6, 2020 | |||||||
| May 6, 2020 | |||||||
| Mar 26, 2020 | |||||||
| Nov 12, 2019 | |||||||
| Aug 7, 2019 | |||||||
| May 7, 2019 | |||||||
| Mar 7, 2019 | |||||||
| Nov 7, 2018 | |||||||
| Aug 8, 2018 | |||||||
| May 10, 2018 | |||||||
| Mar 7, 2018 | |||||||
| Nov 7, 2017 | |||||||
| Aug 8, 2017 | |||||||
| May 9, 2017 | |||||||
| Mar 14, 2017 | |||||||
| Nov 7, 2016 | |||||||
| Aug 8, 2016 | |||||||
| May 5, 2016 | |||||||
| Feb 25, 2016 | |||||||
| Nov 5, 2015 | |||||||
| Aug 10, 2015 |